The world's top 10 pharmaceutical companies and the top 10 best-selling companies in 2021...

Towards the end of the year, people are beginning to pay attention to what will change in the industry in the coming year.
In this year, due to the outbreak, some multinational pharmaceutical companies in the fight against the epidemic drugs and vaccines in the continuous efforts, so that these companies outside the industry visibility and reputation greatly increased, and, in this matter brought about by the halo effect, all pharmaceutical companies in the industry have benefited a lot, most intuitively, pharmaceutical stocks strong, favored by investors.
In addition, a series of multi-billion dollar mergers and acquisitions in 2020 show that multinational pharmaceutical companies are limited by the outbreak, and the industry's record of IPOs and financing this year remains bright, so it can be seen that, unlike other industries, few pharmaceutical companies are facing cash flow drying up as the year approaches, and it is believed that mergers and acquisitions will continue in 2021.
The new coronavirus pandemic will remain the focus of 2021, and the development and listing of vaccines by multinational pharmaceutical companies has entered a critical phase, with the release of trial data, it will become increasingly clear that companies with real potential and strength will begin to focus on which companies can achieve short- or long-term financial benefits.
In 2021, oncology drugs remain the main driver of industry growth, with six of the 10 drugs with the biggest sales growth being anti-tumor drugs, three of which are PD-(L)1, and Therida, which is forecast to be the world's biggest-selling drug by 2023, according to a survey released this month.
Forecast: Top 10 Best Selling Drugs in 2021 (US$100 million): Forecast: The products in the two charts above the largest new drugs sold in 2021 (IND) are noteworthy because they have brought huge sales and significant sales growth to drug companies, while the market performance of the two similar drugs, "O" and "K", also shows that PD-1 has made great progress in the treatment of solid tumors.
Gilead Sciences' new HIV-resistant drug, Vitavi, is expected to reach $8.4 billion in sales in 2021, ranking 8th on the global drug sales list, and despite Gilead Sciences' efforts to expand into the field of oncology, it remains an antiviral drug company based on the sales forecasts above.
And evaluate predicts that even if Adamo monobial-like drugs are on the market, AbbVie's Shumeile remains the world's best-selling drug, and with the benefit of two popular new immunotherapy drugs, Rinvoq and Skyrizi, AbbVie is expected to add $6 billion in new sales next year, remaining the world's largest growing pharmaceutical company.
And Demand for AstraZeneta's three new cancer drugs, Terisha, Infineon and Liptro, is expected to surge next year, pushing AstraZeneta to the second-highest sales in the world next year, and AstraZeneta will benefit from the final growth of drugs such as Repulius, which is acquired from Xinji, and third in the world in new sales.
expects Roche to remain the world's largest drug company with a large portfolio of oncology drugs, with sales expected to reach $51.3 billion, with Novaral and AbbVie in second and third place respectively.
forecast: Top 10 pharmaceutical companies in the world by 2021 (US$ billion)